

## **Publications auxquelles l'ARETASC a participé en 2010**

- 1) Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer.  
Rodrigo Arriaga, Ariane Duvant, Thierry Le Chevalier  
J Clin Oncol volume 28- Number 1 – January 1 – 2010.
- 2) Randomized Phase III trial of Vinorelbine plus Cisplatin compared with observation in completely resected stage IB and II Non Small Lung Cancer; updated survival analysis of JBR- 10.  
Charles Butts, Keyue Ding, Lesley Seymour.  
J Clin Oncol volume 28- Number 1 – January 1 – 2010.
- 3) Abstract TEAM 2010 : Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years , the TEAM trial a prospective, randomized phase III . EBCC 7 (European breast cancer conference) March 2010 Barcelona Spain
- 4) Trial in postmenopausal women with hormone receptor positive early breast cancer. EBCC 7 (European breast cancer conference) March 2010 Barcelona Spain
- 5) Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.  
J.G.H van Nes, C.Seynaeve, S.Jones on behalf of the Tamoxifen and Exemestane adjuvant Multinational (TEAM) trialists.  
British Journal of Surgery 2010 May; 97(5):671-9.PMID20393978
- 6) Pharmacogenetics of Tamoxifen in relation to disease free survival in a dutch cohort of the Tamoxifen Exemestane adjuvant multinational trial.  
V.Dezentjé : ASCO (American Society for Clinical Oncology) juin 2010 meeting.
- 7) Phase III trial carboplatin plus paclitaxel with or without gemcitabine in first line treatment of epithelial ovarian cancer  
Andreas de Bois, Jorn Herrsted, Jalid Sehoudi  
J.Clin.Oncol volume 28 number 27 september 20 -2010
- 8) Distant recurrences at median of 5-years among 9.779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy.  
H.Hortier, JM.Vannetzel, ESMO (European Society for Medical Oncology) abst, October 11, 2010: Gold, 10:45 - 12:30
- 9) Final results from the IFCT-GFPC 0502 phase III study: maintenance therapy in advanced NSCLC with Either Gemcitabine (G) or Erlotinib (E) versus Observation

(O) after Cisplatin-Gemcitabine, induction Chemotherapy (CT) with a predefined second line treatment.

Poster 370 ESMO october 2010

10) Discontinuation during Tamoxifen in the sequential arm of the Team trial of adjuvant endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer: The effect of IES result and subsequent therapy.

C.Van de Velde P5-11-17 Team SABC (San Antonio Breast Cancer) December 2010.

11) The impact of body mass index on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer patients: exploratory analysis from the Team study.

C.Seynaeve et al; San Antonio Breast Cancer Symposium – December 2010.

12) Final results of a prospectively planned biomarker analysis: HER 1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus tamoxifen in the Team pathology sub-study.

Bartlett et al; presentation S2-4 SABC December 2010.

13) Efficacy of Trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study:

The Oncology 2010; 15:799-809

### Revue française :

Hormonothérapie dans le cancer du sein après la ménopause :JMVannetzel  
N° 38- tome 7 – Mars 2010- Réflexions en médecine oncologique.

Avril 2010 : CANCERS : hormonothérapie adjuvante : les dernières actualités entretien avec  
JMVannetzel page 7 revue avril 2010

Mai 2010 : Flash Med epu ; revue bimestrielle de formation médicale continue :  
dossier Le Cancer du Sein ISHH ; page 1-13